Trending Stock News

Wells Fargo Reports Jounce Therapeutics (JNCE) Downgrade from Outperform; Thor Mining PLC (LON:THR) Covered By 2 Bullish Analysts Last Week

Thor Mining PLC (LON:THR) Logo

Among 3 analysts covering Thor Mining PLC (LON:THR), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Thor Mining PLC had 31 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Thor Mining PLC (LON:THR) has “Corporate” rating given on Monday, July 25 by Northland Capital. Northland Capital maintained the stock with “Corporate” rating in Thursday, September 1 report. As per Wednesday, January 18, the company rating was maintained by Northland Capital. The stock of Thor Mining PLC (LON:THR) earned “Corporate” rating by Northland Capital on Monday, August 15. Beaufort Securities maintained Thor Mining PLC (LON:THR) on Tuesday, July 4 with “Speculative Buy” rating. The rating was maintained by Northland Capital on Friday, April 29 with “Corporate”. The stock of Thor Mining PLC (LON:THR) has “Speculative Buy” rating given on Wednesday, August 2 by Beaufort Securities. The rating was maintained by Northland Capital with “Corporate” on Thursday, October 20. As per Wednesday, September 20, the company rating was maintained by Beaufort Securities. Northland Capital maintained the stock with “Speculative Buy” rating in Thursday, September 3 report. See Thor Mining PLC (LON:THR) latest ratings:

In a analysts report revealed to investors on 17 May, Wells Fargo has cut Jounce Therapeutics (JNCE) stock to Market Perform. JNCE’s old rating was Outperform.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $573.98 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on August, 8. They expect $-0.38 earnings per share, down 245.45% or $0.27 from last year’s $-0.11 per share. After $-0.40 actual earnings per share reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 17, 2018, also Nasdaq.com with their article: “Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical …” published on May 16, 2018, Benzinga.com published: “22 Stocks Moving In Thursday’s Pre-Market Session” on May 17, 2018. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Jounce Therapeutics’ (JNCE) CEO Rich Murray on Q1 2018 Results – Earnings Call Transcript” with publication date: May 09, 2018.

The stock increased 6.45% or $1.07 during the last trading session, reaching $17.67. About 650,096 shares traded or 70.78% up from the average. Jounce Therapeutics, Inc. (JNCE) has declined 9.84% since May 17, 2017 and is downtrending. It has underperformed by 21.39% the S&P500.

Among 6 analysts covering Jounce Therapeutics (JNCE), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Jounce Therapeutics has $35.0 highest and $28.0 lowest target. $31’s average target is 75.44% above currents $17.67 stock price. Jounce Therapeutics had 9 analyst reports since February 21, 2017 according to SRatingsIntel. The firm has “Outperform” rating by Robert W. Baird given on Tuesday, February 21. Wells Fargo initiated the shares of JNCE in report on Tuesday, February 21 with “Outperform” rating. Cowen & Co maintained the shares of JNCE in report on Monday, November 13 with “Buy” rating. On Thursday, March 8 the stock rating was maintained by Robert W. Baird with “Buy”. Robert W. Baird maintained Jounce Therapeutics, Inc. (NASDAQ:JNCE) rating on Tuesday, September 12. Robert W. Baird has “Buy” rating and $30.0 target. JP Morgan initiated it with “Overweight” rating and $28.0 target in Tuesday, February 21 report. The firm has “Buy” rating given on Wednesday, June 7 by Cowen & Co.

The stock increased 4.00% or GBX 0.09 during the last trading session, reaching GBX 2.21. About 296,953 shares traded. Thor Mining PLC (LON:THR) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *